Abstract:Background: Long QT syndrome 3 (LQT3) is caused by SCN5A mutations. Late sodium current (late INa) inhibitors are current-specific to treat patients with LQT3, but the mechanisms underlying mexiletine (MEX) -sensitive (N1325S and R1623Q) and -insensitive (M1652R) mutations remains to be elucidated.Methods: LQT3 patients with causative mutations were treated with oral MEX following i.v. lidocaine. Whole-cell patch-clamp techniques and molecular remodeling were used to determine the mechanisms underlying the sensitivity to MEX.Results: Intravenous administration of lidocaine followed by MEX orally in LQT patients with N1325S and R1623Q sodium channel mutation shortened QTc interval, abolished arrhythmias, and completely normalized the ECG. In HEK293 cells, the steady-state inactivation curves of the M1652R channels were rightward shifted by 5.6 mV relative to the WT channel. In contrast, the R1623Q mutation caused a leftward shift of the steady-state inactivation curve by 15.2 mV compared with WT channel, and N1325S mutation did not affect steady-state inactivation (n = 5–13, P < 0.05). The extent of the window current was expanded in all three mutant channels compared with WT. All three mutations increased late INa with the greatest amplitude in the M1652R channel (n = 9–15, P < 0.05). MEX caused a hyperpolarizing shift of the steady-state inactivation and delayed the recovery of all three mutant channels. Furthermore, it suppressed late INa in N1325S and R1623Q to a greater extent compared to that of M1652R mutant channel. Mutations altered the sensitivity of Nav1.5 to MEX through allosteric mechanisms by changing the conformation of Nav1.5 to become more or less favorable for MEX binding. Late INa inhibitors suppressed late INa in N1325S and R1623Q to a greater extent than that in the M1652R mutation (n = 4–7, P < 0.05).Conclusion: The N1325S, R1623Q, and M1652R mutations are associated with a variable augmentation of late INa, which was reversed by MEX. M1652R mutation changes the conformation of Nav1.5 that disrupt the inactivation of channel affecting MEX binding, corresponding to the poor response to MEX. The lidocaine test, molecular modeling, and drugs screening in cells expressing mutant channels are useful for predicting the effectiveness of late INa inhibitors.

Lidocaine Attenuation Testing: an in Vivo Investigation of Putative LQT3-associated Variants in the SCN5A-encoded Sodium Channel.

Abstract 10669: Phenytoin, an Anti-Epileptic Sodium Channel Blocker, May Be a Novel Therapy for Type 3 Long Qt Syndrome Mediated by the Lidocaine-Insensitive SCN5A-F1760C Variant

PO-646-04 FUNCTIONAL CHARACTERIZATION AND IDENTIFICATION OF A THERAPEUTIC FOR A NOVEL SCN5A-F1760C VARIANT CAUSING TYPE 3 LONG QT SYNDROME REFRACTORY TO ALL GUIDELINE DIRECTED THERAPIES

Functional Characterization and Identification of a Therapeutic for a Novel SCN5A-F1760C Variant Causing Type 3 Long QT Syndrome Refractory to All Guideline-Directed Therapies.

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3

Long QT Syndrome Patients With Mutations of the SCN5A and HERG Genes Have Differential Responses to Na + Channel Blockade and to Increases in Heart Rate

A rare loss-of-function SCN5A variant is associated with lidocaine-induced ventricular fibrillation

Long Qt Syndrome Patients With Mutations Of The Scn5a And Herg Genes Have Differential Responses To Na+ Channel Blockade And To Increases In Heart-Rate - Implications For Gene-Specific Therapy

The SCN5A Mutation A1180V is Associated with Electrocardiographic Features of LQT3

Α-1-syntrophin Mutation and the Long-QT Syndrome

Clinical Aspects of Type 3 Long-QT Syndrome: an International Multicenter Study.

Discovery and Characterization of a Monogenetic Insult, Caveolin-3-v37l, That Precipitated Oligo-Proteomic Perturbations Governing Repolarization Reserve.

The Common SCN5A Mutation R1193Q Causes LQTS-type Electrophysiological Alterations of the Cardiac Sodium Channel

Left cardiac sympathetic denervation reduces skin sympathetic nerve activity in patients with Long QT syndrome

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

Lidocaine-Induced Brugada Syndrome Phenotype Linked to a Novel Double Mutation in the Cardiac Sodium Channel

Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome

A Pore-Localizing CACNA1C-E1115K Missense Mutation, Identified in a Patient with Idiopathic QT Prolongation, Bradycardia, and Autism Spectrum Disorder, Converts the L-type Calcium Channel into a Hybrid Nonselective Monovalent Cation Channel.

Denaturing High-Performance Liquid Chromatography Quickly And Reliably Detects Cardiac Ion Channel Mutations In Long Qt Syndrome